Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
We hypothesized that short-term treatment with haloperidol induces insulin resistance through
a mechanistic route that is independent of weight gain. We therefore treated healthy
non-obese men with haloperidol for 8 days, and studied the impact of these intervention on
glucose and lipid metabolism by hyperinsulinemic euglycemic clamp, isotope dilution
technology and indirect calorimetry.